Latest News and Press Releases

BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...

Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...

Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

Clinical evaluation of AM-301 nasal spray in allergen protection progressingLaunch of AM-301 expected in selected markets towards the end of second quarter 2021 Phase 2 trial with AM-125 in acute...

Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...

Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises  AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing  Hamilton,...

Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet...

Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...